コンテンツへスキップ
Merck
  • Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-Stage Pediatric Cardiomyopathy.

Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-Stage Pediatric Cardiomyopathy.

Frontiers in physiology (2018-01-10)
Ilse A E Bollen, Marijke van der Meulen, Kyra de Goede, Diederik W D Kuster, Michiel Dalinghaus, Jolanda van der Velden
要旨

Dilated cardiomyopathy amongst children (pediatric cardiomyopathy, pediatric CM) is associated with a high morbidity and mortality. Because little is known about the pathophysiology of pediatric CM, treatment is largely based on adult heart failure therapy. The reason for high morbidity and mortality is largely unknown as well as data on cellular pathomechanisms is limited. Here, we assessed cardiomyocyte contractility and protein expression to define cellular pathomechanisms in pediatric CM. Explanted heart tissue of 11 pediatric CM patients and 18 controls was studied. Contractility was measured in single membrane-permeabilized cardiomyocytes and protein expression was assessed with gel electrophoresis and western blot analysis. We observed increased Ca

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
プロテインキナーゼ A ウシ心臓由来, ≥0.8 units/μg protein, lyophilized powder